Scancell Share Discussion Threads

[marcusl2] 31/8/2023 15:35

I see that Orenetide failed phase II. You will need to join a gym instead Loz ;-)

[miavoce] 31/8/2023 15:24

Ah sorry, I thought you mean something unexpected.

[inanaco] 31/8/2023 15:20

if scancell is presenting SCIB1 and Modi1 then yes ...

RNS must be issued

[miavoce] 31/8/2023 15:18

RNS coming...is this genuine ?

[inanaco] 31/8/2023 14:18

RNS coming

[inanaco] 31/8/2023 14:17

Ruckrover the champion for device's everywhere

another OCD issue

[ruckrover] 31/8/2023 13:45

Lozan, Ah yes, the filter, the last bastion of those incapable of defending their case in a civilised manner.

[marcusl2] 31/8/2023 10:47

Ruck, well done. You got two votes from your friends in Broadmoor and Charenton.

I don`t know what education or lack of it you have had but maybe you should enrol for some rudimentary `basic English for dummies' night classes.

Quote from the article;

"But it’s clear that the verbiage also applies to the company’s desire to grow its pharma unit."

(Another knuckle trailer back on the filter)

[the real lozan] 31/8/2023 09:44

Perspctive,,, Every cloud and all that -
One GOOD thing WE ALL CAN take from the 5536 "the "Risk" of buying in France" outdated 'news' is that =
One CAN take it, that the OLD info that "France hits British second homeowners with 60pc tax surcharge" ...even more...there is less chance/RISK of us being poluted by the unwanted arrival of the disturbed Car Park attendant.
.
Anyway - Suns out, blue skies, a pleasant 27 C in the sun on S facing terrace...NO narky Nano
What's not to like and enjoy ???

[ruckrover] 31/8/2023 09:15

Marcus,"Johnson & Johnson's appetite for M&A is "voracious.""You omitted the word "device""Johnson & Johnson's appetite for device M&A is "voracious."(Not drugs or oncology)The company they bought makes miniature heart pumps. Did you actually read the article or do you just paste irrelevant links willy nilly?

[the real lozan] 31/8/2023 08:56

An observation -
This morning, Mrs Lozan and I,have been watchung,approx 25 mtrs from our livingroom windows, a group of BeeEaters perched in the tops of 'the dead tree', taking turns to flick off and return with their 'breakfasts'. (Not sure exactly on what they are feeding)
To clarify, the 'dead tree' does not stand alone, it protrudes from atop a dense growth of lower Fig trees.
Figs of the green.yellow variety.
We also have the more abundant trees/bushes of the purple variety on our property... which we utilise for shade in the summer months, yet allow us to profit from any heat.sunshine in the winter months when the Figs loose their foliage.
The thing of note, is that the BeeEaters are not sporting the vibrant colours they display in early spring/summer when they arrive here from Africa to breed.
Despite all the FEAR mongers manipulations..there are worthwhile signs that the REAL world still exists.... IF one knows where/how to look.

[panama7] 31/8/2023 07:34

Inane, that just goes to show your ignorance of what is happening across the World. Try doing some research into UN Agenda 2030 and educate yourself.

[marcusl2] 30/8/2023 21:26

Johnson & Johnson's appetite for M&A is “voracious.”

[inanaco] 30/8/2023 20:16

latest headline .....

France hits British second homeowners with 60pc tax surcharge
Thousands more local authorities granted power to apply council tax surcharges

the "Risk" of buying in France

[marcusl2] 30/8/2023 09:07

I’d forget RC365 shares! I think these 2 penny stocks could be next. In the middle of June, RC365 Holdings (LSE:RCGH) shares were trading at 25p. They’ve since exploded higher, currently trading at 125p. Clearly, there’s higher volatility when investing in penny stocks. Yet the potential rewards can be huge. Even though RC365 shares could keep flying higher, I’ve probably missed the big move. But here are two other stocks I believe have the potential to rally.





Waiting for a move
The other penny stock that I’m looking at is Scancell Holdings (LSE:SCLP). The stock has fallen by 24% over the past year, with a share price of just 9.5p.

The company is a clinical stage biopharmaceutical company. Ideally, it needs to be able to take products from research stage, through clinical trials and get them all approved in order to generate sizeable profits.

Currently, the business is loss-making. It doesn’t have any revenue coming in through the door, but has sizeable expenses to fund the research and trials. Although this is a risk, it’s the same practice that all in the same business line go through.

Yet on the other hand, it has £24m cash on hand (as of the latest report). It burned through £4.4m in the previous six months, so it has a big buffer to keep running operations for a while.

In the meantime, I believe it has a good shot at taking either Modi-1 or SCIB1 products to the market in 2024. Modi-1 had a recent 44% disease control rate with test patients of aggressive cancer that had exhausted other options. This shows me that the potential take-up of the product if it reaches the market could be very large. As soon as investors get a smell that this could be the case, I’d expect the share price to rally.

[marcusl2] 29/8/2023 14:22

over 15 years of experience across healthcare in FTSE and NASDAQ-listed companies, investment banking, and audit.

[markingtime] 29/8/2023 11:59

The imminent SCIB1 results and the Modi-1 results over the coming months (probably published across at least two RNSs in my view) are both undeniable inflection points. Antibody deals/milestones are also possible.

[inanaco] 29/8/2023 11:44

and replace it with one of yours ?

sorry i am not a manic depressive person

i could not go through life like you ...

[ruckrover] 29/8/2023 11:27

Inan, That's a bit strong. The only thing I could possibly destroy is your delusions.

[inanaco] 29/8/2023 10:08

“Now I am become Death, the destroyer of worlds.”

Ruck ... the optimist

[ruckrover] 29/8/2023 09:56

" near-term inflection points"Would that be the same "near term" Goodfellow and Holloway talked about in 2013 and 2016?